An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs.

114Citations
Citations of this article
134Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

G protein-coupled receptors (GPCRs) represent 50-60% of the current drug targets. There is no doubt that this family of membrane proteins plays a crucial role in drug discovery today. Classically, a number of drugs based on GPCRs have been developed for such different indications as cardiovascular, metabolic, neurodegenerative, psychiatric, and oncologic diseases. Owing to the restricted structural information on GPCRs, only limited exploration of structure-based drug design has been possible. Much effort has been dedicated to structural biology on GPCRs and very recently an X-ray structure of the beta2-adrenergic receptor was obtained. This breakthrough will certainly increase the efforts in structural biology on GPCRs and furthermore speed up and facilitate the drug discovery process.

Cite

CITATION STYLE

APA

Lundstrom, K. (2009). An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs. Methods in Molecular Biology (Clifton, N.J.). https://doi.org/10.1007/978-1-60327-317-6_4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free